Tarsus Pharmaceuticals, Inc. stock: filings, catalysts and timeline
Sign in to follow
FundamentalsWhat is this?HideToo few of the required measures on file
How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.
Source: SEC XBRL financial statements.
ValueWhat is this?HideToo few of the required measures on file
How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.
Source: SEC XBRL financial statements and end-of-day prices.
News flowWhat is this?HideBalanced
What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.
Source: SEC EDGAR 8-K filings and FDA approvals.
MomentumWhat is this?HideBalanced
The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.
Source: End-of-day prices.
SafetyWhat is this?HideStrong
The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.
Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.
Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on News flow, Momentum and Safety, and the missing score lowers its Evidence strength.
Discovery Gap: Very high (89/100) · Gap confidence 64/100
Documented progress is running well ahead of market attention.
Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.
What is this?Hide
How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.
Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.
How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.
Gap confidenceWhat is this?HideStrong 64/100How fully AIR could measure this Gap.
How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.
Evidence strengthWhat is this?HideModerate 44/100Support behind the full AIR read, not only the Gap.
How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.
This month at a glance
Evidence timeline
- Expected
Tue 23 Feb · expected 10-K
Last year filed 23 Feb 2026.
Thu 6 May · expected 10-Q
Last year filed 6 May 2026.
- Filed
Tue 3 Nov · 8-K
8-K · Item 2.02 — Results of operations
XDEMVY achieved record Q3 2026 net sales of $194.6M (+64% YoY). Company surpassed 1M bottles dispensed and $1B cumulative sales since launch. Pipeline advanced with multiple clinical milestones expected H1 2027. Two strategic acquisitions completed.
Tue 3 Nov · 10-Q
Thu 10 Sep · 8-K
8-K · Items 2.01, 8.01 — Acquisition or disposal of assets
Tarsus completed acquisition of Alkeus Pharmaceuticals, adding gildeuretinol (ALK-001), a Phase 3 oral investigational medicine for Stargardt's disease with Breakthrough Therapy and Orphan Drug designations. NORTHSTAR Phase 3 trial topline data anticipated in 2029.
Thu 6 Aug · 8-K
Thu 6 Aug · 10-Q
Quarterly report (10-Q), period ending 30 Jul 2026
Thu 6 Aug · 8-K
Thu 6 Aug · 8-K
Mon 13 Jul · 8-K
Wed 8 Jul · 8-K
8-K · Items 1.01, 3.02, 8.01 — Acquisition completed
Tarsus Pharmaceuticals acquired iRenix Medical for $37.5M cash plus 607,093 shares, with up to $490M in milestone payments and revenue-sharing on future net sales. Acquisition completed July 6, 2026.
Mon 29 Jun · 8-K
Wed 6 May · 8-K
Wed 6 May · 10-Q
Quarterly report (10-Q), period ending 1 May 2026
Mon 23 Feb · 8-K
Mon 23 Feb · 10-K
Annual report (10-K), FY2026
Wed 18 Feb · 8-K
Mon 12 Jan · 8-K
Tue 4 Nov · 10-Q
Quarterly report (10-Q), period ending 29 Oct 2025
Tue 4 Nov · 8-K
Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.
Ask AIR
What would change our view
Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.